Bill Text: TX HB124 | 2013-2014 | 83rd Legislature | Introduced

NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Relating to the addition of Salvia divinorum and its derivatives and extracts to Penalty Group 3 of the Texas Controlled Substances Act.

Spectrum: Moderate Partisan Bill (Republican 5-1)

Status: (Passed) 2013-06-14 - Effective on 9/1/13 [HB124 Detail]

Download: Texas-2013-HB124-Introduced.html
  83R1216 JSC-D
 
  By: Anderson H.B. No. 124
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to the addition of Salvia divinorum and its derivatives
  and extracts to Penalty Group 3 of the Texas Controlled Substances
  Act.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Section 481.104(a), Health and Safety Code, is
  amended to read as follows:
         (a)  Penalty Group 3 consists of:
               (1)  a material, compound, mixture, or preparation that
  contains any quantity of the following substances having a
  potential for abuse associated with a stimulant effect on the
  central nervous system:
                     Methylphenidate and its salts; and
                     Phenmetrazine and its salts;
               (2)  a material, compound, mixture, or preparation that
  contains any quantity of the following substances having a
  potential for abuse associated with a depressant effect on the
  central nervous system:
                     a substance that contains any quantity of a
  derivative of barbituric acid, or any salt of a derivative of
  barbituric acid not otherwise described by this subsection;
                     a compound, mixture, or preparation containing
  amobarbital, secobarbital, pentobarbital, or any salt of any of
  these, and one or more active medicinal ingredients that are not
  listed in any penalty group;
                     a suppository dosage form containing amobarbital,
  secobarbital, pentobarbital, or any salt of any of these drugs, and
  approved by the United States Food and Drug Administration for
  marketing only as a suppository;
                     Alprazolam;
                     Amobarbital;
                     Bromazepam;
                     Camazepam;
                     Chlordiazepoxide;
                     Chlorhexadol;
                     Clobazam;
                     Clonazepam;
                     Clorazepate;
                     Clotiazepam;
                     Cloxazolam;
                     Delorazepam;
                     Diazepam;
                     Estazolam;
                     Ethyl loflazepate;
                     Fludiazepam;
                     Flurazepam;
                     Glutethimide;
                     Halazepam;
                     Haloxzolam;
                     Ketazolam;
                     Loprazolam;
                     Lorazepam;
                     Lormetazepam;
                     Lysergic acid, including its salts, isomers, and
  salts of isomers;
                     Lysergic acid amide, including its salts,
  isomers, and salts of isomers;
                     Mebutamate;
                     Medazepam;
                     Methyprylon;
                     Midazolam;
                     Nimetazepam;
                     Nitrazepam;
                     Nordiazepam;
                     Oxazepam;
                     Oxazolam;
                     Pentazocine, its salts, derivatives, or compounds
  or mixtures thereof;
                     Pentobarbital;
                     Pinazepam;
                     Prazepam;
                     Quazepam;
                     Secobarbital;
                     Sulfondiethylmethane;
                     Sulfonethylmethane;
                     Sulfonmethane;
                     Temazepam;
                     Tetrazepam;
                     Tiletamine and zolazepam in combination, and its
  salts.  (some trade or other names for a tiletamine-zolazepam
  combination product:  Telazol, for tiletamine:  2-(ethylamino)-
  2-(2-thienyl)-cyclohexanone, and for zolazepam:  4-(2-
  fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-
  e](1,4)-d diazepin-7(1H)-one, flupyrazapon);
                     Triazolam;
                     Zaleplon;
                     Zolpidem; and
                     Zopiclone;
               (3)  Nalorphine;
               (4)  a material, compound, mixture, or preparation
  containing limited quantities of the following narcotic drugs, or
  any of their salts:
                     not more than 1.8 grams of codeine, or any of its
  salts, per 100 milliliters or not more than 90 milligrams per dosage
  unit, with an equal or greater quantity of an isoquinoline alkaloid
  of opium;
                     not more than 1.8 grams of codeine, or any of its
  salts, per 100 milliliters or not more than 90 milligrams per dosage
  unit, with one or more active, nonnarcotic ingredients in
  recognized therapeutic amounts;
                     not more than 300 milligrams of dihydrocodeinone
  (hydrocodone), or any of its salts, per 100 milliliters or not more
  than 15 milligrams per dosage unit, with a fourfold or greater
  quantity of an isoquinoline alkaloid of opium;
                     not more than 300 milligrams of dihydrocodeinone
  (hydrocodone), or any of its salts, per 100 milliliters or not more
  than 15 milligrams per dosage unit, with one or more active,
  nonnarcotic ingredients in recognized therapeutic amounts;
                     not more than 1.8 grams of dihydrocodeine, or any
  of its salts, per 100 milliliters or not more than 90 milligrams per
  dosage unit, with one or more active, nonnarcotic ingredients in
  recognized therapeutic amounts;
                     not more than 300 milligrams of ethylmorphine, or
  any of its salts, per 100 milliliters or not more than 15 milligrams
  per dosage unit, with one or more active, nonnarcotic ingredients
  in recognized therapeutic amounts;
                     not more than 500 milligrams of opium per 100
  milliliters or per 100 grams, or not more than 25 milligrams per
  dosage unit, with one or more active, nonnarcotic ingredients in
  recognized therapeutic amounts;
                     not more than 50 milligrams of morphine, or any of
  its salts, per 100 milliliters or per 100 grams with one or more
  active, nonnarcotic ingredients in recognized therapeutic amounts;
  and
                     not more than 1 milligram of difenoxin and not
  less than 25 micrograms of atropine sulfate per dosage unit;
               (5)  a material, compound, mixture, or preparation that
  contains any quantity of the following substances:
                     Barbital;
                     Chloral betaine;
                     Chloral hydrate;
                     Ethchlorvynol;
                     Ethinamate;
                     Meprobamate;
                     Methohexital;
                     Methylphenobarbital (Mephobarbital);
                     Paraldehyde;
                     Petrichloral; and
                     Phenobarbital;
               (6)  Peyote, unless unharvested and growing in its
  natural state, meaning all parts of the plant classified
  botanically as Lophophora, whether growing or not, the seeds of the
  plant, an extract from a part of the plant, and every compound,
  manufacture, salt, derivative, mixture, or preparation of the
  plant, its seeds, or extracts;
               (7)  unless listed in another penalty group, a
  material, compound, mixture, or preparation that contains any
  quantity of the following substances having a stimulant effect on
  the central nervous system, including the substance's salts,
  optical, position, or geometric isomers, and salts of the
  substance's isomers, if the existence of the salts, isomers, and
  salts of isomers is possible within the specific chemical
  designation:
                     Benzphetamine;
                     Cathine [(+)-norpseudoephedrine];
                     Chlorphentermine;
                     Clortermine;
                     Diethylpropion;
                     Fencamfamin;
                     Fenfluramine;
                     Fenproporex;
                     Mazindol;
                     Mefenorex;
                     Modafinil;
                     Pemoline (including organometallic complexes and
  their chelates);
                     Phendimetrazine;
                     Phentermine;
                     Pipradrol;
                     Sibutramine; and
                     SPA [(-)-1-dimethylamino-1,2-diphenylethane];
               (8)  unless specifically excepted or unless listed in
  another penalty group, a material, compound, mixture, or
  preparation that contains any quantity of the following substance,
  including its salts:
                     Dextropropoxyphene (Alpha-(+)-4-dimethylamino-
  1,2-diphenyl-3-methyl-2-propionoxybutane); [and]
               (9)  an anabolic steroid, including any drug or
  hormonal substance, or any substance that is chemically or
  pharmacologically related to testosterone, other than an estrogen,
  progestin, dehydroepiandrosterone, or corticosteroid, and promotes
  muscle growth, including the following drugs and substances and any
  salt, ester, or ether of the following drugs and substances:
                     Androstanediol;
                     Androstanedione;
                     Androstenediol;
                     Androstenedione;
                     Bolasterone;
                     Boldenone;
                     Calusterone;
                     Clostebol;
                     Dehydrochlormethyltestosterone;
                     Delta-1-dihydrotestosterone;
                     Dihydrotestosterone (4-dihydrotestosterone);
                     Drostanolone;
                     Ethylestrenol;
                     Fluoxymesterone;
                     Formebulone;
                     Furazabol;
                     13beta-ethyl-17beta-hydroxygon-4-en-3-one;
                     4-hydroxytestosterone;
                     4-hydroxy-19-nortestosterone;
                     Mestanolone;
                     Mesterolone;
                     Methandienone;
                     Methandriol;
                     Methenolone;
                     17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha-
  androstane;
                     17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha-
  androstane;
                     17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-
  ene;
                     17alpha-methyl-4-hydroxynandrolone;
                     Methyldienolone;
                     Methyltestosterone;
                     Methyltrienolone;
                     17alpha-methyl-delta-1-dihydrotestosterone;
                     Mibolerone;
                     Nandrolone;
                     Norandrostenediol;
                     Norandrostenedione;
                     Norbolethone;
                     Norclostebol;
                     Norethandrolone;
                     Normethandrolone;
                     Oxandrolone;
                     Oxymesterone;
                     Oxymetholone;
                     Stanozolol;
                     Stenbolone;
                     Testolactone;
                     Testosterone;
                     Tetrahydrogestrinone; and
                     Trenbolone; and
               (10)  Salvia divinorum, unless unharvested and growing
  in its natural state, meaning all parts of that plant, whether
  growing or not, the seeds of that plant, an extract from a part of
  that plant, and every compound, manufacture, salt, derivative,
  mixture, or preparation of that plant, its seeds, or extracts,
  including Salvinorin A.
         SECTION 2.  This Act takes effect September 1, 2013.
feedback